Give patients control of their psoriatic symptoms with CIMZIA1,18,19

CIMZIA offers rapid skin improvement that can last

CIMZIA® (certolizumab pegol) is indicated for the treatment of adults with moderate to severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapy, and adults with active psoriatic arthritis (PsA)1

Explore the data

Co-primary endpoints were PASI 75 and PGA 0/1. A majority of patients responded at Week 16, and responder rates were maintained to Week 48 with 200 mg every other week maintenance dosing.1,18,19

CIMZIA has 6 approved indications1


Moderate to Severe Plaque Psoriasis in adults who are candidates for systemic therapy or phototherapy


Moderately to Severely Active Crohn’s Disease if response to conventional therapy is inadequate


Moderately to Severely Active Rheumatoid Arthritis


Active Psoriatic Arthritis


Active Ankylosing Spondylitis

NR axSpA

Non-radiographic Axial Spondyloarthritis